Released May 3, 2022, after the close
10-Q filed May 3, 2022, 33 days after period end · 0001558370-22-006809
Q1 2022 · 10-Q
Revenue$16.74M$16.74M −79.3% vs Q1 2021−18.0% vs Q4 2021
Net Income-$27.45M-$27.45M N/M vs Q1 2021N/M vs Q4 2021
EPS Diluted-$0.16-$0.16 N/M vs Q1 2021no prior Q4 2021 on file
Operating Income-$26,261,000N/M
Operating Cash Flow-$25,637,000N/M
Free Cash Flowderived-$25,861,000N/M
Margins · derived
Operating margin-156.9%−208.5 pt vs Q1 2021
Net margin-164.0%−212.8 pt vs Q1 2021
What the release said
The release
Same quarter
| Metric | Q1 2022 | Q1 2021 | Q1 2020 | Q1 2019 |
|---|---|---|---|---|
| Revenue | $16.74M | $81.02M | $55.76M | $12.62M |
| Net Income | -$27.45M | $39.50M | $21.24M | -$17.60M |
| EPS Diluted | -$0.16 | $0.22 | $0.13 | -$0.11 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Rigel Pharmaceuticals Inc · CIK 1034842 · Engraved from SEC EDGAR